Maryam Oskoui

Montreal, QC, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 156 publications

Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations: Report of the AAN Guidelines Subcommittee and the American Headache Society.

Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations: Report of the AAN Guidelines Subcommittee and the American Headache Society.

Journal: Neurology
Published: August 31, 2026

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society.

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society.

Journal: Neurology
Published: August 31, 2026

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society.

Systematic Review of Pharmacologic Treatment for Migraine Prevention in Adults: Report of the AAN Guidelines Subcommittee and the American Headache Society.

Journal: Headache
Published: July 29, 2026

Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations: Report of the AAN Guidelines Subcommittee and the American Headache Society.

Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations: Report of the AAN Guidelines Subcommittee and the American Headache Society.

Journal: Headache
Published: July 29, 2026

Predicting Functional Decline in Duchenne Muscular Dystrophy: Advancing Trial Readiness and Patient Counseling.

Predicting Functional Decline in Duchenne Muscular Dystrophy: Advancing Trial Readiness and Patient Counseling.

Journal: Neurology
Published: May 26, 2026

Vamorolone Safety, Pharmacokinetics, and Exploratory Efficacy in Duchenne Muscular Dystrophy: A Phase II, Nonrandomized, Multiple-Dose Study in 2-<4-Year-Old Boys.

Vamorolone Safety, Pharmacokinetics, and Exploratory Efficacy in Duchenne Muscular Dystrophy: A Phase II, Nonrandomized, Multiple-Dose Study in 2-<4-Year-Old Boys.

Journal: Neurology
Published: May 15, 2026

In response to: Personalized antioxidant supplementation improves muscle strength, physical activity, and quality of life in patients with FSHD1: A real-world longitudinal study. Laoudj-Chenivesse D, Arbogast S, Raynaud De Mauverger E, Fedou C, Debroize E, Hugon G, Pincemail J, Picot MC, Cristol JP, Mercier J, Portet F. Free Radic Biol Med. 2026 Feb 28; 248: 424-435.

In response to: Personalized antioxidant supplementation improves muscle strength, physical activity, and quality of life in patients with FSHD1: A real-world longitudinal study. Laoudj-Chenivesse D, Arbogast S, Raynaud De Mauverger E, Fedou C, Debroize E, Hugon G, Pincemail J, Picot MC, Cristol JP, Mercier J, Portet F. Free Radic Biol Med. 2026 Feb 28; 248: 424-435.

Journal: Free radical biology & medicine
Published: April 26, 2026

Author Correction: Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial.

Author Correction: Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial.

Journal: Nature medicine
Published: January 28, 2026

Broad lessons from negative trials in rare diseases.

Broad lessons from negative trials in rare diseases.

Journal: The Lancet. Neurology
Published: January 21, 2026

Management of Functional Seizures Practice Guideline Executive Summary: Report of the AAN Guidelines Subcommittee.

Management of Functional Seizures Practice Guideline Executive Summary: Report of the AAN Guidelines Subcommittee.

Journal: Neurology
Published: December 10, 2025

Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to < 18-year-old boys with duchenne muscular dystrophy.

Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to < 18-year-old boys with duchenne muscular dystrophy.

Journal: Journal of neurology
Published: November 11, 2025

Quebec Spinal Muscular Atrophy Newborn Screening Program: The First Year Experience.

Quebec Spinal Muscular Atrophy Newborn Screening Program: The First Year Experience.

Journal: International journal of neonatal screening
Published: September 05, 2025
Showing 1-12 of 156

Last Updated: 09/26/2026